FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293507309> ?p ?o ?g. }

• W4293507309 endingPage "221" @default.
• W4293507309 startingPage "215" @default.
• W4293507309 abstract "Background This study was conducted to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) using 177 Lu-DOTA0-Tyr3-octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs). Methods Sixteen patients with pathologically verified NETs including eight females and eight males were enrolled in this study. Before PRRT, the patients underwent 68 Ga-DOTATATE positron emission tomography/computed tomography or 99m Tc-octreotide scintigraphy for evaluation of somatostatin receptor expression. Response to treatment was assessed according to the Response Evaluation Criteria In Solid Tumors (RECIST) classified as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). In addition, for evaluation of toxicity, monthly blood analysis was performed including hematology, renal function (creatinine) test, and liver function test. The Eastern Cooperative Oncology Group (ECOG) status performance was applied to estimate the patients' general condition in a scale of 0 (fully active) to 5 (dead). In addition, overall survival (OS) was calculated as the time interval from the start of PRRT to death from any reason. Results Sixteen patients including eight females and eight males with a median age of 60.5 years (range: 24-74) were enrolled in this study. The patients underwent PRRT with a median cycle of 3.5 (range: 1-7) and a median dose of 20.35 (range: 7.4-49.95 GBq). At the end of data collection, PR, CR, SD, and PD were seen in 11, 2, 1, and 2 patients according to the RECIST, respectively. Three patients expired during or after the PRRT period. The median ECOG and Karnofsky Performance Scale was 1.5 and 75 before PRRT, which improved significantly to 1 and 80 after PRRT, respectively ( p < 0.05). According to the Kaplan-Meier test, the median OS was 23 months (95% confidence interval: 7.90-38.09). According to the National Cancer Institute's Common Terminology Criteria for Adverse Events, three patients showed grade I and three patients showed grade II leucopenia. Furthermore, three and seven patients had grade II and grade I anemia, respectively. Conclusion Since PRRT using 177 Lu-DOTATATE has a favorable response rate and few adverse effects and improves the quality of life in NETs, it can be used as an effective therapeutic option, especially in nonoperative, metastatic, and progressive NETs." @default.
• W4293507309 created "2022-08-30" @default.
• W4293507309 creator A5001802500 @default.
• W4293507309 creator A5009774150 @default.
• W4293507309 creator A5011681963 @default.
• W4293507309 creator A5038041661 @default.
• W4293507309 creator A5038279860 @default.
• W4293507309 creator A5046783736 @default.
• W4293507309 creator A5057462120 @default.
• W4293507309 creator A5061077694 @default.
• W4293507309 creator A5064777652 @default.
• W4293507309 creator A5071586528 @default.
• W4293507309 creator A5079511375 @default.
• W4293507309 date "2022-08-16" @default.
• W4293507309 modified "2023-09-26" @default.
• W4293507309 title "Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment" @default.
• W4293507309 cites W2019607817 @default.
• W4293507309 cites W2031048655 @default.
• W4293507309 cites W2036509237 @default.
• W4293507309 cites W2042265119 @default.
• W4293507309 cites W2066696295 @default.
• W4293507309 cites W2069386429 @default.
• W4293507309 cites W2079932483 @default.
• W4293507309 cites W2100477040 @default.
• W4293507309 cites W2102617530 @default.
• W4293507309 cites W2108613323 @default.
• W4293507309 cites W2125398839 @default.
• W4293507309 cites W2148617171 @default.
• W4293507309 cites W2149214723 @default.
• W4293507309 cites W2154755646 @default.
• W4293507309 cites W2291637351 @default.
• W4293507309 cites W2315552101 @default.
• W4293507309 cites W2573369749 @default.
• W4293507309 cites W2886043747 @default.
• W4293507309 cites W2900654004 @default.
• W4293507309 cites W2963657976 @default.
• W4293507309 cites W3015918073 @default.
• W4293507309 doi "https://doi.org/10.1055/s-0042-1755412" @default.
• W4293507309 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36060085" @default.
• W4293507309 hasPublicationYear "2022" @default.
• W4293507309 type Work @default.
• W4293507309 citedByCount "0" @default.
• W4293507309 crossrefType "journal-article" @default.
• W4293507309 hasAuthorship W4293507309A5001802500 @default.
• W4293507309 hasAuthorship W4293507309A5009774150 @default.
• W4293507309 hasAuthorship W4293507309A5011681963 @default.
• W4293507309 hasAuthorship W4293507309A5038041661 @default.
• W4293507309 hasAuthorship W4293507309A5038279860 @default.
• W4293507309 hasAuthorship W4293507309A5046783736 @default.
• W4293507309 hasAuthorship W4293507309A5057462120 @default.
• W4293507309 hasAuthorship W4293507309A5061077694 @default.
• W4293507309 hasAuthorship W4293507309A5064777652 @default.
• W4293507309 hasAuthorship W4293507309A5071586528 @default.
• W4293507309 hasAuthorship W4293507309A5079511375 @default.
• W4293507309 hasBestOaLocation W42935073091 @default.
• W4293507309 hasConcept C126322002 @default.
• W4293507309 hasConcept C159641895 @default.
• W4293507309 hasConcept C170493617 @default.
• W4293507309 hasConcept C2776297358 @default.
• W4293507309 hasConcept C2778822529 @default.
• W4293507309 hasConcept C2779066768 @default.
• W4293507309 hasConcept C2779134260 @default.
• W4293507309 hasConcept C2779984678 @default.
• W4293507309 hasConcept C2780306776 @default.
• W4293507309 hasConcept C2781025020 @default.
• W4293507309 hasConcept C2989005 @default.
• W4293507309 hasConcept C2993559085 @default.
• W4293507309 hasConcept C3017732841 @default.
• W4293507309 hasConcept C71924100 @default.
• W4293507309 hasConcept C80115893 @default.
• W4293507309 hasConcept C90924648 @default.
• W4293507309 hasConceptScore W4293507309C126322002 @default.
• W4293507309 hasConceptScore W4293507309C159641895 @default.
• W4293507309 hasConceptScore W4293507309C170493617 @default.
• W4293507309 hasConceptScore W4293507309C2776297358 @default.
• W4293507309 hasConceptScore W4293507309C2778822529 @default.
• W4293507309 hasConceptScore W4293507309C2779066768 @default.
• W4293507309 hasConceptScore W4293507309C2779134260 @default.
• W4293507309 hasConceptScore W4293507309C2779984678 @default.
• W4293507309 hasConceptScore W4293507309C2780306776 @default.
• W4293507309 hasConceptScore W4293507309C2781025020 @default.
• W4293507309 hasConceptScore W4293507309C2989005 @default.
• W4293507309 hasConceptScore W4293507309C2993559085 @default.
• W4293507309 hasConceptScore W4293507309C3017732841 @default.
• W4293507309 hasConceptScore W4293507309C71924100 @default.
• W4293507309 hasConceptScore W4293507309C80115893 @default.
• W4293507309 hasConceptScore W4293507309C90924648 @default.
• W4293507309 hasIssue "03" @default.
• W4293507309 hasLocation W42935073091 @default.
• W4293507309 hasLocation W42935073092 @default.
• W4293507309 hasLocation W42935073093 @default.
• W4293507309 hasLocation W42935073094 @default.
• W4293507309 hasOpenAccess W4293507309 @default.
• W4293507309 hasPrimaryLocation W42935073091 @default.
• W4293507309 hasRelatedWork W1518474861 @default.
• W4293507309 hasRelatedWork W1541368151 @default.
• W4293507309 hasRelatedWork W1862826322 @default.
• W4293507309 hasRelatedWork W2092706522 @default.

• next